A Phase 3, Study of Adjuvant Immunotherapy with Nivolumab

To compare the efficacy, as measured by recurrence free survival (RFS), provided by nivolumab versus ipilimumab in subjects with completely resected Stage IIIb/c or Stage IV NED melanoma who are at high-risk for recurrence.

September 25, 2015